About Paul Enck

Prof. Dr. Paul Enck, Director of Research, Dept. of Psychosomatic Medicine and Psychotherapy, University Hospital Tübingen, Germany. His main interests are gut functions in health and disease, including functional and inflammatory bowel disorders, the role of the gut microbiota, regulation of eating and food intake and its disorders, of nausea, vomiting and motion sickness, and the psychophysiology and neurobiology of the placebo response, with specific emphasis on age and gender contributions. He has published more than 170 original data paper in scientific, peer-reviewed journals, and more than 250 book chapters and review articles. He is board member/treasurer of the European Society of Neurogastroenterology and Motility and of the German Society of Neurogastroenterology and Motility, and has served as reviewer for many international journals and grant agencies.

Irritable bowel syndrome (IBS) is one of the most common functional gastrointestinal disorders, affecting more than 10% of the population, with the highest impact in women. Although its origin is still unknown, reduced gut microbial diversity could be involved in its development.

A recent study, led by Dr. Claire Steves, a clinical research fellow from the Department of Twin Research & Genetic Epidemiology, King’s College London, identified several associations between host frailty and gut microbiota diversity, which might offer potential targets for intervention to strengthen healthy ageing.

Gestational diabetes mellitus (GDM) is one of the most frequent metabolic complications of pregnancy and its prevalence is up to 12% in developed countries. Nowadays, several studies are investigating new therapies for glucose control that may complement diet, exercise, and pharmacological therapies.

A recent study, led by Dr. Andrew S. Neish from the Department of Pathology and Laboratory Medicine at Emory University School of Medicine in Atlanta, found that Akkermansia muciniphila and other anaerobic bacteria may promote gut healing in mice.

Research shows that host-microbe interactions can regulate immune and metabolic pathways. Here, Fu and colleagues investigated the connection between the microbiota and selected risk factors for cardiovascular disease in humans: abnormal blood lipid levels and high body mass.

Authors of this paper attempted a meta-analysis of 56 studies on single-strain and multi-strain probiotics for the treatment of IBS, but trials were so heterogeneous when it came to probiotic concentration, duration of treatment, and methodology, that the meta-analysis was abandoned.

Go to Top